A two-part Phase II laceration study began in January 2025, with Part IB recently
completed following the successful
treatment of 24 patients at an
Emergency Department (ED) and
Phase I unit in Kyiv, Ukraine.
Part 2a is scheduled to
begin in Q3 2025.